-
Eikon Therapeutics Inks Licensing Deals and Raises Funds for Drug Pipeline Expansion
•
US biotech company Eikon Therapeutics has announced three in-licensing deals this week, one of which includes a partnership with China-based Impact Therapeutics. The agreement grants Eikon exclusive rights to co-develop, manufacture, and commercialize PARP1 inhibitors, including IMP1734, in markets outside of Greater China. The financial details of the licensing fee…
